In the original publication, Figs. 3 and 5 and the final sentence in the final paragraph of Results/ Sensitivity Analyses were incorrectly published. The corrected statement and the figures are given below.
Correction to: Diabetes Ther https://doi.org/10.1007/s13300-019-0630-6
In the original publication, Figs. 3 and 5 and the final sentence in the final paragraph of Results/ Sensitivity Analyses were incorrectly published. The corrected statement and the figures are given below.
Additionally, the last few lines under the heading 'Sensitivity Analyses' should read as:
At a willingness-to-pay threshold of DKK 250,000 per QALY gained (a representative value based on GBP 20,000 in the UK), the probabilities of once-weekly semaglutide 0.5 mg and 1 mg being considered cost-effective were 72.4% and 96.5%, respectively, versus dulaglutide 1.5 mg (Fig. 5) . 
